Recro Pharma, Inc.·4/A

Oct 2, 6:41 PM ET

Graff Fred 4/A

4/A · Recro Pharma, Inc. · Filed Oct 2, 2017

Insider Transaction Report

Form 4/AAmended
Period: 2017-09-28
Graff Fred
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2017-09-28+2,00010,000 total
Footnotes (1)
  • [F1]On September 28, 2017, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 2,000 performance-based restricted stock units, which were converted into 2,000 shares of common stock on a one-for-one basis.

Documents

2 files
  • 4
    edgar.xml

    PRIMARY DOCUMENT

  • EX-24

    POWER OF ATTORNEY